Income Statement
CG ONCOLOGY, INC.
CGON
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
- | - |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
- | - |
|
Operating Expenses
|
194.81 | 115.81 |
|
Research & Development
|
116.64 | 82.10 |
|
Selling, General & Administrative
|
73.53 | 33.70 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-194.81 | -115.81 |
|
Non-Operating Income
|
29.78 | 26.63 |
|
Interest Income
|
29.93 | 26.62 |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
-0.15 | 26.63 |
|
Income Before Tax
|
- | - |
|
Income Tax Expense
|
- | - |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-161.00 | -88.04 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-193.37 | -115.77 |
|
Earnings Per Share (Basic)
|
-2.08 | -1.41 |
|
Diluted EPS
|
-2.08 | -1.41 |
|
Weighted Average Shares
|
77.30 | 62.50 |
|
Diluted Weighted Avg Shares
|
77.30 | 62.50 |
|
Comprehensive Income
|
- | - |